PFK 15

Biological Activity

PFK 15 is originally reported to be a selective PFKFB3 inhibitor (IC₅₀ = 207 nM); a more recent report failed to demonstrate activity in a PFKFB3 kinase assay. Selective for PFKFB3 over a panel of 96 kinases. Reduces glucose uptake and induces apoptosis in H522 lung adenocarcinoma and Jurkat T cell leukemia cells. Suppresses glucose uptake and tumor growth, and inhibits metastasis of Lewis lung carcinoma cell xenografts in mice.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Targeting the Warburg effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
   Brooke et al.
   Bioorg.Med.Chem., 2014;22:1029
2. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
   Clem et al.
   Mol.Cancer Ther., 2013;12:1461

Product Datasheets